186 related articles for article (PubMed ID: 32801790)
1. Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
Kokai-Kun JF; Le C; Trout K; Cope JL; Ajami NJ; Degar AJ; Connelly S
Infect Drug Resist; 2020; 13():2521-2535. PubMed ID: 32801790
[TBL] [Abstract][Full Text] [Related]
2. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
3. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
Connelly S; Bristol JA; Hubert S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
J Appl Microbiol; 2017 Jul; 123(1):66-79. PubMed ID: 28245091
[TBL] [Abstract][Full Text] [Related]
4. SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31979034
[TBL] [Abstract][Full Text] [Related]
5. The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Kokai-Kun JF; Roberts T; Coughlin O; Sicard E; Rufiange M; Fedorak R; Carter C; Adams MH; Longstreth J; Whalen H; Sliman J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052855
[TBL] [Abstract][Full Text] [Related]
6. Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137766
[TBL] [Abstract][Full Text] [Related]
7. Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Front Microbiol; 2019; 10():101. PubMed ID: 30804903
[TBL] [Abstract][Full Text] [Related]
8. Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
AIMS Public Health; 2019; 6(4):477-487. PubMed ID: 31909068
[TBL] [Abstract][Full Text] [Related]
9. Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
Connelly S; Parsley T; Ge H; Kaleko M
Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30654495
[TBL] [Abstract][Full Text] [Related]
10. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
[TBL] [Abstract][Full Text] [Related]
11. Destination shapes antibiotic resistance gene acquisitions, abundance increases, and diversity changes in Dutch travelers.
D'Souza AW; Boolchandani M; Patel S; Galazzo G; van Hattem JM; Arcilla MS; Melles DC; de Jong MD; Schultsz C; ; Dantas G; Penders J
Genome Med; 2021 Jun; 13(1):79. PubMed ID: 34092249
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
Kokai-Kun JF; Bristol JA; Setser J; Schlosser M
Int J Toxicol; 2016 May; 35(3):309-16. PubMed ID: 26700136
[TBL] [Abstract][Full Text] [Related]
13. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
14. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner.
Montassier E; Valdés-Mas R; Batard E; Zmora N; Dori-Bachash M; Suez J; Elinav E
Nat Microbiol; 2021 Aug; 6(8):1043-1054. PubMed ID: 34226711
[TBL] [Abstract][Full Text] [Related]
15. Machine Learning Leveraging Genomes from Metagenomes Identifies Influential Antibiotic Resistance Genes in the Infant Gut Microbiome.
Rahman SF; Olm MR; Morowitz MJ; Banfield JF
mSystems; 2018; 3(1):. PubMed ID: 29359195
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.
Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962
[TBL] [Abstract][Full Text] [Related]
17. The gastrointestinal antibiotic resistome in pediatric leukemia and lymphoma patients.
MacDonald T; Dunn KA; MacDonald J; Langille MGI; Van Limbergen JE; Bielawski JP; Kulkarni K
Front Cell Infect Microbiol; 2023; 13():1102501. PubMed ID: 36909730
[TBL] [Abstract][Full Text] [Related]
18. Impact of antibiotics on gut microbiome composition and resistome in the first years of life in low- to middle-income countries: A systematic review.
Luchen CC; Chibuye M; Spijker R; Simuyandi M; Chisenga C; Bosomprah S; Chilengi R; Schultsz C; Mende DR; Harris VC
PLoS Med; 2023 Jun; 20(6):e1004235. PubMed ID: 37368871
[TBL] [Abstract][Full Text] [Related]
19. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome.
Connelly S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
Anaerobe; 2018 Oct; 53():82-93. PubMed ID: 29689301
[TBL] [Abstract][Full Text] [Related]
20. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.
Bulow C; Langdon A; Hink T; Wallace M; Reske KA; Patel S; Sun X; Seiler S; Jones S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2018 Nov; 3(6):. PubMed ID: 30463925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
